You are here: Home » PTI Stories » National » News
Business Standard

Lupin's Nagpur facility gets Establishment Inspection Report from US FDA

Shares of Lupin were today trading at Rs 903 per scrip on BSE, down 0.07 per cent from its previous close

Press Trust of India  |  New Delhi 

Drug firm today said it has received an Establishment Inspection Report (EIR) from the US health regulator after the successful inspection of its facility.

The plant was inspected by the United States Food and Drug Administration (USFDA) in May 2018, said in a filing to

Commenting on the development, MD Nilesh Gupta said, "The successful completion of the facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."

Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the facility without making any observations.

of Lupin were today trading at Rs 903 per scrip on BSE, down 0.07 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Fri, August 24 2018. 15:15 IST
RECOMMENDED FOR YOU